Twenty-five years of HIV management

Journal of the Royal Society of Medicine

Volumn 100, Issue 8, 2007, Pages 363-366

  Jayasuriya, Ashini ^a   Robertson, C ^a   Allan, P S ^a  

^a Hospital of Coventry and Warwickshire   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; ETRAVIRINE; HLA B57 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTHRALGIA; CIRCUMCISION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIARRHEA; DRUG MEGADOSE; DYSPNEA; EPIDEMIC; FEVER; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION; LIVER TOXICITY; LONG TERM CARE; LYMPHADENOPATHY; NAUSEA; POLYMERASE CHAIN REACTION; PREGNANCY; PREVALENCE; RASH; REVIEW; SEXUAL TRANSMISSION; SIDE EFFECT; TUBERCULOSIS; VIRUS RESISTANCE; VOMITING;

EID: 34548066053     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.100.8.363     Document Type: Review

References (18)

1. Centers for Disease Control. Pneumocystis Pneumonia - Los Angeles. Morb Mort Weekly Rep 1981; 30: 1-3
2. WHO/UNAIDS. AIDS Epidemic Update 2005. WHO/UNAIDS, 2005. Available at www.who.int/hiv/epiupdates (accessed April 2006)
3. The Health Protection Agency. Epidemiological data/Surveillance Methods. The Health Protection Agency. Available at www.hpa.org.uk/ infections/topics_az/hiv_and_sti/hiv/hiv.htm (accessed April 2006)
4. Mocroft A, et al. AIDS across Europe, 1994-98: the EuroSIDA Study. Lancet 2000;356:291-6
5. The Health Protection Agency. TB Update March 2006, TB Surveillance Update 2000-2004. The Health Protection Agency. Available at www.hpa.org.uk/infections/topics_az/tb/pdf/newsletter_2006.pdf (accessed April 2006)
6. WHO. Treating 3 million by 2005. Making it happen. The WHO strategy, 2003. Available at www.who.int/3by5/publications/documents (accessed April 2006)
7. WHO. 3 by 5 progress reports. WHO/UNAIDS. June 2005. Available at www.who.int/3by5/en (accessed April 2006)
8. British HIV Association guidelines for the treatment of HIV-infected adults with anti-retroviral therapy (2005). HIV Med 2005;6(Suppl 2):1-61
9. Bernard E. Do CCR5 inhibitors have a future? Aids Treatment Update 2006;153
10. Berenguer, et al. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort. J AIDS 2006;41:154-9
11. UK collaborative Group on HIV Drug Resistance, UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretrovirals in routine clinical practice. AIDS 2005;19:487-94
12. Cardo DM, et al. A case controlled study of HIV seroconversion in health care workers after percutaneous exposure to HIV infected blood: clinical and public health implications. N Engl J Med 1997;337:1485
13. Sperling RS, et al. Maternal viral load, zidovudine treatment and the risk of transmission of Human Immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9
14. Fisher M, et al. BASHH guideline: UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure, Int J STD AIDS 2006;17:81-92
15. British HIV Association. Guidelines for the Management of HIV Infection in Pregnant Women and the Prevention of Mother-to-Child Transmission of HIV. BHIVA, 31 March 2005. Available at www.bhiva.org (accessed in April 2006)
16. Connor E, et al. Reduction of maternal-infant transmission of HIV Type-1 with zidovudine therapy. N Engl J Med 1994;331:1173-80
17. Das S. HIV and increased risk of cardiovascular diseases. Sexual Health 2005;2:219-21
18. Mary-Krause M, et al. Clinical Epidemiology Group from the French Hospital Database: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479- 86